Chemotherapy-Induced Neutropenia, Anemia and Thrombocytopenia  among Filipino Breast Cancer Patients on Adjuvant Chemotherapy

Tia, Lou Jorel P.; Lui, Arthur; Chua, Noel S.; Strebel, Heinrik Martin Jude S.

doi:10.47895/amp.v49i2.967

Cited by 5 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The magnitude of neutropenia was inline with the study done in United states (59%) (8). But it was higher than those studies done in Japan (17.2%), and Philipins (5%) (3,5,9,10). This might be due to diferent reasons; Firstly, in this study, participants were blacks who might have lower white blood cell and neutrophil count relative to white people (39).…”

Section: Discussioncontrasting

confidence: 56%

“…In the current study, the magnitude of thrombocytopenia was higher than the studies done in Philipins (1%) and United states (9.6%) (5,21). The study included metastatic breast cancer patients, which may produce the possibility to develop higher risks of thrombocytopenia (5).…”

Section: Discussionmentioning

confidence: 62%

“…Conventional chemothrepaeutic agents still remain to be the treatment of choice for breast cancer in the developing countries. Therefore, doxorubicin-cyclophosphamide (AC) and AC followed by paclitaxel (AC-T) are a standard chemotherapy regimen commonly used worldwide to treat breast cancer (3)(4)(5)(6). These anticancer drugs produce profound chemotherapeutic effects in neoplastic cells of having high growth fractions (e.g.…”

Section: Introductionmentioning

confidence: 99%

“…However, they are associated with diverse hematologic toxicities of varying intensity such as chemotherapy induced neutropenia (CIN), febrile neutropenia(NF), anemia (CIA), and thrombocytopenia (CIT), among others. For example, previous studies identi ed that the magnitude of CIN in breast cancer patients treated with AC-T regimen ranged from 5 to 100% (3,5,(7)(8)(9)(10), NF (4.1 to 29.5%) (3,7,(10)(11)(12)(13), CIA (2.8-97.1%) (5,7,8,(14)(15)(16)(17)(18)(19)(20), and CIT (1-42.9%) (5,7,8,14,21). Moreover, around 70% of cancer patients were also developed short and long-term systemic complications (22).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hematologic Toxicities and its Determinants among Breast Cancer Patients Treated with Doxorubicin-Cyclophosphamide Followed by Paclitaxel Regimen in Cancer Centers: Retrospective Cohort Study

Tesfaye¹,

Mekonnen

Abebe

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Clinically, chemotherapy induced neutropenia, febrile neutropenia, thrombocytopenia and anemia were the common toxicities among breast cancer patients treated with doxorubicin-cyclophosphamide followed by paclitaxel regimen. Those toxicities may lead to chemotherapy dose modification, delay and discontinuation that may substantially compromise therapeutic outcomes. Objective To assess hematologic toxicities and its determinants among breast cancer patients treated with doxorubicin-cyclophosphamide followed by paclitaxel regimen in cancer centers, Northwest Ethiopia. Method Retrospective cohort study design was used to collect data among 422 breast cancer patients from Felege-Hiwot Comprehesnsive and Specialized Hospital and University Of Gondar Comprehensive and Specialized Hospital using a structured data abstraction format by employing systematic random sampling technique. The collected data were entered into EPI-data version 3.1 and analysed using IBM SPSS version 26. Association between dependent and independent variables was determined by using bivariate and multivariate logistic regression analysis where p < 0.05 was considered to be statistically significant. Results Among the study participants, more than half (76.1%) and (51.4%) patients had ductal type histology and stage III cancer, respectively, and almost all (98.9%) breast cancer patients performed modified radical mastectomy. Besides, nearly half of patients (46%) had poor ECOG PS. In the current study, the occurrence of neutropenia, anemia, thrombocytopenia and febrile neutropenia were 61.8%, 44.1%, 16.4% and 10%, respectively. Significant association with neutropenia was seen in patients; age ≥ 43years [AOR = 1.68, 95%CI (1.13,2.52)] and rular residency [AOR = 1.76,95%CI (1.16,2.67)]. Whereas stage III and IV cancer [AOR = 2.40,95%CI (1.17,4.94)] was significantly associated with febrile neutropenia. Furthermore, association with anemia was also seen in patients with mixed type histology [AOR = 4.71, 95%CI (1.43,15.53)], lobular type histology [AOR = 0.51,95%CI (0.29,0.87)], stage III and IV cancer [AOR = 1.73,95%CI (1.14,2.63) and disease comorbidity [AOR = 2.11,95%CI (1.04,4.30)]. Likewise, rular residency [AOR = 1.72,95%CI (1.01,2.91)], age ≥ 43years [AOR = 1.75,95%CI (1.02,3.02)] and stage III and IV cancer [AOR = 2.13,95%CI (1.22,3.74) were significantly associated with thrombocytopenia. Conclusion The magnitude of hematologic toxicities in patients treated with doxorubicin-cyclophosphamide followed by paclitaxel was high in the study setting. Age, rular residence, stage of cancer, disease comorbidity, mixed and lobular type histology were factors associated with chemotherapy induced hematologic toxicities.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hematologic Toxicities and its Determinants among Breast Cancer Patients Treated with Doxorubicin-Cyclophosphamide Followed by Paclitaxel Regimen in Cancer Centers: Retrospective Cohort Study

Tesfaye¹,

Mekonnen

Abebe

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Anemia, neutropenia, dan trombositopenia dialami beberapa pasien kanker di Filipina setelah pemberian kemoterapi. Hal ini menunjukkan kemoterapi dapat menginduksi timbulnya penyakit tersebut (Tia, Lui, Chua, & Strebel, 2015).…”

unclassified

Antiproliferation potential of Botto-botto (Chromolaena odorata L.) leaves methanol extract fraction against HeLa Cell Line

Rusdi¹,

Haeria²,

Hamzah³

et al. 2020

ad-dawaa.j.pharm.sci

View full text Add to dashboard Cite

Botto-botto (Chromolaena odorata L.) adalah salah satu tanaman yang secara empiris digunakan daunnya oleh masyarakat Sulawesi Selatan sebagai obat luka dan antiinflamasi. Penelitian ini bertujuan untuk menguji potensi antiproliferasi ekstrak metanol daun Botto-botto terhadap sel kanker (HeLa) dan sel normal (Vero) dengan metode MTT (Microculture Tetrazolium Salt). Daun kering diekstraksi dengan metode maserasi menggunakan pelarut metanol, filtrat kemudian dikeringkan. Ekstrak kemudian dipartisi dengan pelarut etil asetat. Ekstrak etil asetat dari ekstrak metanol yang diperoleh difraksinasi menggunakan kromatografi kolom cair vakum menggunakan pelarut yang berbeda tingkat kepolarannya. Setiap fraksi kemudian diuji aktivitas antiproliferasi menggunakan metode MTT pada sel kanker HeLa dan sel normal Vero dengan parameter persen penghambatan pertumbuhan sel. Indeks selektivitas dihitung dari rasio persen penghambatan pertumbuhan sel kanker dibanding sel normal. Hasil penelitian ini menunjukkan bahwa fraksi A, B, C, D, E, F, dan G dari hasil fraksinasi ekstrak etil asetat memiliki indeks selektivitas pada sel HeLa masing-masing sebesar 0,845; 3,387; 2,004; 1,508; 1,625; 1,284; 1,299. Hasil ini membuktikan bahwa fraksi B dari ekstrak metanol daun Botto-botto berpotensi dikembangkan sebagai agen kemoterapi dalam meningkatkan efektivitas pengobatan kanker leher rahim.

show abstract

ANALYSIS OF MYELOSUPPRESSION IN POST-CHEMOTHERAPY BREAST CANCER PATIENTS (A Study at Division of Hematology and Medical Oncology Airlangga University Hospital)

Yulistiani,

Utomo,

Romadhon

et al. 2024

Preprint

View full text Add to dashboard Cite

Backgrounds Myelosuppression is decreased bone marrow activity that can be caused by chemotherapy which lowers the formation of blood cells and manifests as anaemia, neutropenia, leukopenia, and thrombocytopenia. Objective This study aims to analyze the post-chemotherapy myelosuppression in breast cancer patients and the chemotherapy regimen used during chemotherapy associated with blood parameters. Method This study was conducted in observational retrospective design. Data were taken from patients’ medical record that went on chemotherapy during January 2021- December 2022. Results The result showed that 97% patients had myelosuppression with the significance statistic’s analysis P<0,05. The chemotherapy regimens used in breast cancer patients are AC-T, TAC, Paclitaxel-Carboplatin, TC, AC-TH, and TCH. This study found myelosuppression in several regimens: anaemia grade I-II in patients with AC-T regimen, neutropenia grade I-IV in patients with TCH regimen, leukopenia grade I-IV in patients with TC regimen, and thrombocytopenia grade I in patients with Paclitaxel-Carboplatin regimen. The incidence of delayed chemotherapy in patients due to myelosuppression is 18%. Conclusion Based on this study, all the regimens used had myelosuppression side effect. The highest incidence of myelosuppression occurred in patient with TAC and TCH regimen. Myelosuppression can cause delayed therapy, dose reduction, and drug substitution.

show abstract

Chemotherapy-Induced Neutropenia, Anemia and Thrombocytopenia among Filipino Breast Cancer Patients on Adjuvant Chemotherapy

Abstract: ...

Cited by 5 publications

References 0 publications

Hematologic Toxicities and its Determinants among Breast Cancer Patients Treated with Doxorubicin-Cyclophosphamide Followed by Paclitaxel Regimen in Cancer Centers: Retrospective Cohort Study

Hematologic Toxicities and its Determinants among Breast Cancer Patients Treated with Doxorubicin-Cyclophosphamide Followed by Paclitaxel Regimen in Cancer Centers: Retrospective Cohort Study

Antiproliferation potential of Botto-botto (Chromolaena odorata L.) leaves methanol extract fraction against HeLa Cell Line

ANALYSIS OF MYELOSUPPRESSION IN POST-CHEMOTHERAPY BREAST CANCER PATIENTS (A Study at Division of Hematology and Medical Oncology Airlangga University Hospital)

Contact Info

Product

Resources

About